Lataa...
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
PURPOSE: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation. The ai...
Tallennettuna:
| Julkaisussa: | J Cancer Res Clin Oncol |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7382655/ https://ncbi.nlm.nih.gov/pubmed/32385709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03239-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|